
|Articles|June 25, 2019
AbbVie to Acquire Allergan
Advertisement
AbbVie Inc. and Allergan plc have announced that they have entered into a definitive transaction agreement under which AbbVie will acquire Allergan for approximately $63 billion. The combined company will consist of several franchises with focus across immunology, hematologic oncology, medical aesthetics, neuroscience, women's health, eye care, and virology.
Learn all about the acquisition, right
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
ACT Brief: Hidden RBQM Value, Rare Disease Patient Partnership, and Safety Perception in IBD
2
What This Study Means for Sponsors Still Struggling to Justify RBQM at Scale
3
Why Payment Performance Has Become an Operational Brand for Sponsors: Q&A with Patrick Mizer, Ledger Run
4
Beyond Compliance: NetraMark's Joseph Geraci, PhD, on Making AI-Driven Patient Subgroups Explainable
5




